Announcement of the Resolutions of the 14th Meeting of the 8th Supervisory Board of Shanghai Pharmaceuticals Group Co., Ltd.
Securities code: 601607 Securities abbreviation: Shanghai Pharmaceuticals No.: Lin 2025-097
Shanghai Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the Fourteenth Meeting of the Eighth Supervisory Board
The Company's Supervisory Committee and all supervisors guarantee that there are no false records, misleading statements or major omissions in this announcement, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
The 14th meeting of the eighth session of the Supervisory Board of Shanghai Pharmaceuticals Group Co., Ltd. (hereinafter referred to as the "Company") (hereinafter referred to as the "meeting") was held on October 30, 2025 in Conference Room 1101, Shanghai Pharmaceutical Building, No. 200 Taicang Road, Shanghai. 3 supervisors were expected to attend this meeting, and 3 supervisors were actually present, which complied with the "Company Law of the People's Republic of China" and the Company's Articles of Association on the quorum for the meeting of the Supervisory Board. This meeting was chaired by Chairman of the Board of Supervisors Xu Lili. The following proposals were reviewed and approved at this meeting:
1. "2025 Third Quarter Report"
The preparation and review procedures of the company's third quarter report for 2025 comply with the provisions of laws, regulations, the company's articles of association and the company's internal management system;
The content and format of the company's third quarter report for 2025 comply with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the information contained truly reflects the company's business management and financial status and other matters for the first three quarters of 2025;
Before putting forward this opinion, the company's board of supervisors found no violation of confidentiality regulations by those involved in the preparation and review of the third quarter report for 2025.
Voting results: 3 votes in favor, 0 votes against, 0 abstentions
2. "2025 Semi-annual Profit Distribution Plan"
The company achieved a consolidated net profit of RMB 4,458,864,876.61 (unaudited) attributable to shareholders of listed companies in the first half of 2025. It is planned to pay 10 shares to all shareholders based on the total share capital of 3,708,361,809 shares as of June 30, 2025. A cash dividend of RMB 1.20 (tax included) will be distributed for each share, and the total cash dividend to be distributed is RMB 445,003,417.08 (tax included), accounting for 9.98% of the consolidated net profit attributable to shareholders of listed companies in the first half of 2025. There will be no conversion of capital reserve funds into share capital in the first half of 2025.
If the company's total share capital changes between the date of implementation of equity distribution and the equity registration date, the company plans to maintain the amount of distribution per share unchanged based on the total share capital on the registration date of implementation of equity distribution, and adjust the total profit distribution accordingly.
Voting results: 3 votes in favor, 0 votes against, 0 abstentions
The proposal still needs to be submitted to the company's shareholders' meeting for review.
Announcement is hereby made.
Board of Supervisors of Shanghai Pharmaceutical Group Co., Ltd.
October 31, 2025